At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 31 enrolled
Drug / intervention
OPTISONdrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Contrast Enhanced Voiding Urosonography (ceVUS) With the Intravesical Administration of the Ultrasound Contrast Agent OPTISON TM (Trademark) for Vesicoureteral Reflux Detection and Urethral Imaging in Children.
In Brief
A Phase 2 clinical trial evaluating OPTISON for Vesico-Ureteral Reflux. Completed, enrolled 31 participants across 1 site.
Detailed Summary
In this clinical trial the investigators aim to evaluate the diagnostic feasibility and safety of ceVUS with the intravesical use of OPTISON for vesicoureteral reflux detection and urethral imaging in children.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsVesico-Ureteral Reflux
CountriesUnited States
Collaborators--
Timeline
Phase 2CompletedFinished
201520162017201820192020202120222023202420252026
Enrollment StartJul 2014
First PostedJul 2014
Primary CompletionMar 2016
Study CompletionMar 2017
TodayJul 2026
First PostedJul 31, 2014
Enrollment StartJul 1, 2014
Primary CompletionMar 1, 2016
Study CompletionMar 1, 2017
TodayJul 2, 2026
Enrollment to primary: 1.7 yearsPosted 11.9 years ago
Interventions
OPTISONdrug
Contrast enhanced Voiding Urosonography (ceVUS) with intravesical administration of OPTISON for vesicoureteral reflux detection and urethral imaging in children. Voiding Cystourethrography (VCUG) examination will be subsequently performed as part of the standard care.